Q-omics provides the consensus-scored PCDH9-AS3 profile across patient tissues and cancer cell-line models. PCDH9-AS3 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PCDH9-AS3 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, PCDH9-AS3 RNA expression shows 9,605 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight BLCA, KIRC, and COAD as cancer lineages where PCDH9-AS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDH9-AS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDH9-AS3 survival associations across molecular data types. PCDH9-AS3 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDH9-AS3 RNA expression–survival associations across cancer types. High PCDH9-AS3 expression shows unfavorable associations in BLCA, ACC, LGG, CESC and ESCA, but favorable associations in LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PCDH9-AS3 RNA expression.
This table summarizes PCDH9-AS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PCDH9-AS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDH9-AS3 shows lower tumor expression in KIRC. The KIRC box plot shows higher PCDH9-AS3 RNA expression in normal versus tumor tissue (log2 FC = −0.016, t-test p = .012).
This table shows molecular features associated with PCDH9-AS3 in patient tissues and cancer cell lines. In patient samples, PCDH9-AS3 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
